Evaluating the Effect of Candesartan vs Placebo in Prevention of Trastuzumab-associated Cardiotoxicity

NCT00459771 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

210

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: AT1 blocker candesartan
DRUG: Placebo

Sponsor

The Netherlands Cancer Institute

Collaborators

[object Object]
[object Object]